852
Participants
Start Date
June 6, 2018
Primary Completion Date
December 31, 2021
Study Completion Date
January 31, 2022
Xpert Bladder Cancer Monitor
The Xpert Bladder Cancer Monitor Assay is a qualitative in vitro diagnostic test designed to monitor for the recurrence of bladder cancer in patients previously diagnosed with bladder cancer. It should be used in conjunction with other clinical measures to assess disease recurrence. The test provides a fast and accurate result, is non-invasive and easy to perform.The test utilizes a voided urine specimen and measures the level of five target mRNAs (ABL1, CRH, IGF2, UPK1B, ANXA10) by means of real-time, reverse transcription-polymerase chain reaction (RT-PCR).
CHU Toulouse / Institut Universitaire du Cancer Toulouse Oncopole, Toulouse
Sahlgrenska University Hospital, Gothenburg
University of Regensburg, Regensburg
University Clinic for Urology and Andrology, Salzburg
Teaching Hospital Motol, Prague
Klinikum Braunschweig, Braunschweig
Humanitas University - Gradenigo Hospital of Turin, Turin
Instituto Valenciano de Oncologia, Valencia
Sunderland City Hospital, Sunderland
Medical University of Vienna, Vienna
Academic Medical Center, Amsterdam
Fundacio Puigvert, Barcelona
Royal Surrey County Hospital, Guildford
Lead Sponsor
Axonal-Biostatem
INDUSTRY
Stève Consultants
UNKNOWN
Cepheid
INDUSTRY